Compare PLX & DAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLX | DAVA |
|---|---|---|
| Founded | 1993 | 2000 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.5M | 170.2M |
| IPO Year | 1996 | 2015 |
| Metric | PLX | DAVA |
|---|---|---|
| Price | $2.00 | $2.86 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $12.00 | ★ $13.50 |
| AVG Volume (30 Days) | ★ 771.4K | 481.4K |
| Earning Date | 05-12-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $52,744,000.00 | N/A |
| Revenue This Year | $36.81 | N/A |
| Revenue Next Year | N/A | $4.07 |
| P/E Ratio | ★ $8.91 | $20.02 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.34 | $2.74 |
| 52 Week High | $3.19 | $16.06 |
| Indicator | PLX | DAVA |
|---|---|---|
| Relative Strength Index (RSI) | 45.35 | 30.39 |
| Support Level | $1.87 | N/A |
| Resistance Level | $2.17 | $3.58 |
| Average True Range (ATR) | 0.07 | 0.22 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 35.09 | 9.40 |
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.